pharma · Glioblastoma · Unresectable or metastatic soft tissue sarcoma
Philogen
Philogen S.p.A.
Philogen S.p.A is a pharma organization headquartered in SIENA, IT. Primary therapeutic focus areas include Glioblastoma, Unresectable or metastatic soft tissue sarcoma, Cutaneous Squamous Cell Carcinoma, locally advance
Loc. Bellaria, 35, Sovicille, SIENA 53018, IT HQ
1996 Founded
180 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Loc. Bellaria, 35, Sovicille, SIENA 53018, IT
- Founded
- 1996
- Employees
- 180
- Programs
- 18
- Drugs
- 29
- Patents
- 0
Safety and Early Signs of Efficacy of IL12-L19L19
Phase 1 · other · Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy
Safety and Early Signs of Efficacy of IL12-L19L19 for Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy is a Phase 1 program (other) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Internal code PH-IL12L19L19-01/19
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Philogen S.p.A.
- Phase
- Phase 1
- Modality
- other
- Indication
- Advanced or metastatic carcinomas after previous immune checkpoint blockade therapy
- Status
- active
- Trials
- 1